share_log

Humacyte To Present Phase 3 Results Comparing Efficacy And Safety Of Tissue-Engineered Vessel To AV Fistulas In End-Stage Renal Disease Patients At VEITH Symposium On November 23, 2024

Benzinga ·  Nov 22 08:02
Humacyte To Present Phase 3 Results Comparing Efficacy And Safety Of Tissue-Engineered Vessel To AV Fistulas In End-Stage Renal Disease Patients At VEITH Symposium On November 23, 2024
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment